Drug Profile
Complement C1 inhibitor protein - Takeda Inc
Alternative Names: C1 Esterase Inhibitor (human); C1 INH-nf; C1-INH; Cetor; Cinryze; SHP-616; SHP616 Liquid; TAK-616Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sanquin Blood Supply Foundation
- Developer Prothya BioSolutions; Shire; Shire ViroPharma; Takeda; ViroPharma Incorporated
- Class Anti-ischaemics; Antianaemics; Complement C1 inactivator proteins; Eye disorder therapies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Complement C1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hereditary angioedema
- No development reported Autoimmune haemolytic anaemia; Delayed graft function; Neuromyelitis optica
- Discontinued Myocardial infarction; Paroxysmal nocturnal haemoglobinuria; Transplant rejection
Most Recent Events
- 06 Jun 2019 Shire terminates a phase III trial in Transplant rejection in USA, Canada, Germany, Spain, France, Netherlands because following a pre-scheduled interim analysis performed by the DMC, it was determined that the study met the pre-specified criteria for futility (IV) (NCT02547220)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 21 Jun 2018 Registered for Hereditary angioedema (In children, Prevention) in USA (IV)